ERIS
Eris Lifesciences Limited (ERIS) Stock Analysis
Eris Lifesciences Limited is an Indian pharmaceutical company focused on chronic therapies and branded formulations. It markets cardiometabolic, women's health, and other prescription products to doctors and hospitals. The company has a strong domestic sales footprint. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,149.60
+0.33% 1W | -27.00% 52W
Market Cap
15.9k CR
P/E Ratio
24.5
52W High
₹1740
52W Low
₹1137.9
Div. Yield
1.25%
Beta
-0
50 DMA
₹1297.4
200 DMA
₹1368.9
Profit Margin
20%
Inst. Own.
22.3%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 467 | 505 | 486 | 551 | 720 | 741 | 727 | 705 | 773 | 792 | 807 | 757 | 873 |
| Expenses | 297 | 324 | 311 | 402 | 470 | 477 | 477 | 453 | 496 | 504 | 526 | 484 | 577 |
| Operating Profit | 170 | 181 | 176 | 148 | 250 | 265 | 250 | 252 | 277 | 288 | 282 | 272 | 296 |
| OPM % | 36% | 36% | 36% | 27% | 35% | 36% | 34% | 36% | 36% | 36% | 35% | 36% | 34% |
| Other Income | 1 | 3 | 4 | 15 | 2 | 5 | 4 | 8 | 4 | 3 | -17 | 2 | 2 |
| Interest | 17 | 16 | 18 | 33 | 60 | 59 | 57 | 54 | 49 | 50 | 49 | 46 | 47 |
| Depreciation | 41 | 42 | 46 | 54 | 76 | 80 | 81 | 77 | 71 | 69 | 70 | 70 | 72 |
| Profit before tax | 112 | 126 | 116 | 77 | 116 | 129 | 116 | 129 | 161 | 173 | 145 | 159 | 179 |
| Tax % | 17% | 3% | 12% | -4% | 22% | 25% | 25% | 21% | 22% | 22% | 25% | -75% | 20% |
| Net Profit | 94 | 122 | 101 | 80 | 90 | 96 | 87 | 102 | 125 | 134 | 109 | 279 | 143 |
| EPS in Rs | 6.98 | 9.07 | 7.55 | 5.22 | 6.12 | 6.73 | 6.15 | 6.89 | 8.66 | 8.82 | 7.32 | 20.33 | 10.28 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | 3,129 | 3,230 |
| Expenses | 427 | 425 | 480 | 533 | 637 | 702 | 781 | 858 | 1,146 | 1,332 | 1,876 | 2,009 | 2,092 |
| Operating Profit | 118 | 172 | 269 | 322 | 345 | 372 | 431 | 489 | 539 | 677 | 1,018 | 1,120 | 1,138 |
| OPM % | 22% | 29% | 36% | 38% | 35% | 35% | 36% | 36% | 32% | 34% | 35% | 36% | 35% |
| Other Income | 7 | 3 | 25 | 26 | 31 | 12 | 9 | 22 | 9 | 22 | 18 | -9 | -9 |
| Interest | 0 | 0 | 1 | 11 | 23 | 2 | 2 | 4 | 26 | 85 | 231 | 193 | 191 |
| Depreciation | 16 | 20 | 23 | 26 | 36 | 50 | 43 | 65 | 117 | 183 | 315 | 280 | 281 |
| Profit before tax | 109 | 154 | 270 | 312 | 317 | 331 | 394 | 442 | 405 | 431 | 489 | 639 | 657 |
| Tax % | 18% | 13% | 9% | 6% | 8% | 11% | 10% | 8% | 8% | 8% | 23% | -1% | |
| Net Profit | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 648 | 666 |
| EPS in Rs | 6,489.45 | 9,714.18 | 17.95 | 21.39 | 21.15 | 21.84 | 26.16 | 29.88 | 28.10 | 28.82 | 25.84 | 44.72 | 46.75 |
| Dividend Payout % | -0% | 63% | -0% | -0% | -0% | 13% | 21% | 20% | 26% | -0% | 28% | 16% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 23.0% | 21.0% | 18.0% |
| Profit CAGR | 19.0% | 12.0% | 17.0% |
Shareholding Pattern
Promoters54.83%
FIIs8.39%
DIIs18.18%
Public18.59%
Promoters54.85%
FIIs7.21%
DIIs19.36%
Public18.57%
Promoters54.85%
FIIs6.85%
DIIs20.31%
Public17.97%
Promoters53.92%
FIIs6.39%
DIIs20.35%
Public19.33%
Promoters54.14%
FIIs5.76%
DIIs20.71%
Public19.39%
Promoters52.86%
FIIs14.86%
DIIs10.02%
Public22.27%
Promoters54.90%
FIIs14.27%
DIIs15.63%
Public15.20%
Promoters54.85%
FIIs8.43%
DIIs18.07%
Public18.64%
Promoters53.92%
FIIs6.39%
DIIs20.35%
Public19.33%
Promoters54.14%
FIIs5.76%
DIIs20.71%
Public19.39%
ERIS
Holdings Analysis
Key strengths & risk signals
61
Overall
84
Fundamental
38
Technical
Risks (3)
POOR YEAR! Stock declined 26.8% in the last year.
WEAK POSITION! Current price (1149.8) is below both moving averages.
WEAK! Trading at 1.5% of 52W range - near yearly lows.
Strengths (3)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
OVERSOLD! RSI at 25.4 - potential bounce opportunity.
MARKET ALIGNED! Beta of 1.00 - moves with the market.
Fundamental & Technical Analysis
64Overall
84Fundamental
44Technical
Fundamental Breakdown
Growth Quality
28/30
Revenue CAGR: 23.3% (EXCELLENT, 15/15). Profit CAGR: 17.5% (VERY GOOD, 13/15).
Profit Margin
8/10
GOOD EFFICIENCY! 20.0% profit margin - above average profitability.
PEG Valuation
9/10
FAIRLY VALUED! PEG of 1.40 indicates reasonable valuation.
Dividend Yield
5/10
LOW DIVIDEND! 1.25% yield - minimal income contribution.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 22.63% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (1297.4) is below 200-day average (1368.9) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (1149.6) is below both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
1/10
POOR YEAR! Stock declined 27.0% in the last year.
Volume Sentiment
15/30
BEARISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 91,913 vs down days: 114,029. Ratio: 0.81x
RSI
5/5
OVERSOLD! RSI at 25.3 - potential bounce opportunity.
52W Range
1/5
WEAK! Trading at 1.9% of 52W range - near yearly lows.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - 0.3% (1 week), -15.2% (1 month), -22.8% (3 months).
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
ERIS
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-26 | Concall PDF | |
| Q3FY262026-02-20 | Concall PDF | |
| Q2FY262025-11-14 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ERIS | ₹1,149.60 | 24.5 | 20.0% | 23.3% | 17.5% | -27.0% | 64 | BREAKDOWN | +20.7% | -49.4% | +12.6% | +15.5% |
| APLLTD | ₹792.50 | 22.7 | 8.9% | 9.5% | 25.4% | -14.0% | 74 | CONSOLIDATING UP | +12.1% | -14.6% | +25.7% | +16.4% |
| ALIVUS | ₹1,348.00 | 27.5 | 23.3% | 6.9% | 6.5% | +44.0% | 70 | APPROACHING RESISTANCE | +31.8% | -1.6% | +6.4% | -7.1% |
| JUBLPHARMA | ₹938.90 | 42.4 | 4.1% | 9.8% | – | -12.4% | 54 | BREAKDOWN | -45.1% | -52.7% | +18.2% | -2.2% |
| ASTRAZEN | ₹5,950.50 | 87.7 | 7.0% | 31.3% | 23.6% | -35.3% | 56 | APPROACHING SUPPORT | -32.1% | -15.6% | +29.7% | +18.0% |
| COHANCE | ₹445.60 | 163.2 | 5.0% | 18.3% | -24.2% | -48.9% | 58 | CONSOLIDATING DOWN | -149.3% | -223.0% | -23.1% | -31.8% |
| NATCOPHARM | ₹782.60 | 12.4 | 32.8% | 14.5% | 25.6% | -3.8% | 66 | BREAKDOWN | -57.0% | -22.9% | -44.7% | -0.5% |
| CAPLIPOINT | ₹2,338.20 | 26.8 | 29.1% | 14.3% | 19.4% | +19.8% | 76 | BREAKDOWN | +15.8% | +4.0% | +19.6% | +1.7% |
Data from TradeAlone · Updated daily
